Literature DB >> 19384597

Histaminergic activity in a rodent model of Parkinson's disease.

Przemysław Nowak1, Lukasz Noras, Jerzy Jochem, Ryszard Szkilnik, Halina Brus, Eva Körossy, Jacek Drab, Richard M Kostrzewa, Ryszard Brus.   

Abstract

Rats lesioned shortly after birth with 6-OHDA have been proposed to be a near-ideal model of severe Parkinson's disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (DA) denervation of striatum. There are scarce data that in Parkinson's disease, activity of the central histaminergic system is increased. Therefore, the aim of this study was to determine histamine content in the brain and the effect of histamine receptor antagonists on behavior of adult rats. At 3 days after birth, Wistar rats were pretreated with desipramine (20.0 mg/kg ip) 1 h before bilateral icv administration of the catecholaminergic neurotoxin 6-OHDA (67 microg base, on each side) or saline-ascorbic acid (0.1%) vehicle (control). At 8 weeks levels of DA and its metabolites L: -3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA) were estimated in the striatum and frontal cortex by HPCL/ED technique. In the hypothalamus, hippocampus, frontal cortex, and medulla oblongata, the level of histamine was analyzed by immunoenzymatic method. Behavioral observations (locomotion, exploratory-, oral-, and stereotyped-activity) were additionally made on control and 6-OHDA neonatally lesioned rats. Effects of DA receptor agonists (SKF 38393, apomorphine) and histamine receptor antagonists (e.g., S(+)chlorpheniramine, H(1); cimetidine, H(2); thioperamide, H(3) agonist) were determined. We confirmed that 6-OHDA significantly reduced contents of DA and its metabolites in the brain in adulthood. Histamine content was significantly increased in the hypothalamus, hipocampus, and medulla oblongata. Moreover, in 6-OHDA-lesioned rats behavioral response was altered mainly by thioperamide (H(3) antagonist). These findings indicate that histamine and the central histaminergic system are altered in the brain of rats lesioned to model Parkinson's disease, and that histaminergic neurons exert a modulating role in Parkinsonian 6-OHDA-lesioned rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384597     DOI: 10.1007/s12640-009-9025-1

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  41 in total

1.  Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocytochemical study.

Authors:  A M Snyder; M J Zigmond; R D Lund
Journal:  J Comp Neurol       Date:  1986-03-08       Impact factor: 3.215

2.  The action of chlorpromazine on exploration in pairs of rats.

Authors:  S E File; J H Pope
Journal:  Psychopharmacologia       Date:  1974-07-11

3.  Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice.

Authors:  Yasuhiko Kubota; Chihiro Ito; Eiichi Sakurai; Eiko Sakurai; Takehiko Watanabe; Hiroshi Ohtsu
Journal:  J Neurochem       Date:  2002-11       Impact factor: 5.372

4.  Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine.

Authors:  C Ito; K Onodera; E Sakurai; M Sato; T Watanabe
Journal:  J Pharmacol Exp Ther       Date:  1996-10       Impact factor: 4.030

5.  Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors.

Authors:  E Schlicker; K Fink; M Detzner; M Göthert
Journal:  J Neural Transm Gen Sect       Date:  1993

6.  Pharmacological effects of carcinine on histaminergic neurons in the brain.

Authors:  Zhong Chen; Eiko Sakurai; Weiwei Hu; Chunlei Jin; Yoshinobu Kiso; Motohisa Kato; Takehiko Watanabe; Erqing Wei; Kazuhiko Yanai
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

7.  Involvement of the sympathetic nervous system in the reversal of critical haemorrhagic hypotension by endogenous central histamine in rats.

Authors:  Jerzy Jochem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-28       Impact factor: 3.000

8.  A histamine-containing neuronal system in human brain.

Authors:  P Panula; M S Airaksinen; U Pirvola; E Kotilainen
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

9.  Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats.

Authors:  T W Berger; S Kaul; E M Stricker; M J Zigmond
Journal:  Brain Res       Date:  1985-06-17       Impact factor: 3.252

10.  Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse.

Authors:  J Clapham; G J Kilpatrick
Journal:  Eur J Pharmacol       Date:  1994-07-01       Impact factor: 4.432

View more
  11 in total

Review 1.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

2.  Effect of pre- and postnatal manganese exposure on brain histamine content in a rodent model of Parkinson's disease.

Authors:  Ryszard Brus; Jerzy Jochem; Przemysław Nowak; Marta Adwent; Dariusz Boroń; Halina Brus; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2011-08-06       Impact factor: 3.911

3.  Thioperamide, an H₃ receptor antagonist prevents [³H]glucose uptake in brain of adult rats lesioned as neonates with 5,7-dihydroxytryptamine.

Authors:  Jadwiga Jośko; Jacek Drab; Przemysław Nowak; Ryszard Szkilnik; Eva Körossy; Dariusz Boroń; Halina Brus; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

4.  Ontogenetic serotoninergic lesioning alters histaminergic activity in rats in adulthood.

Authors:  Jadwiga Jośko; Jacek Drab; Jerzy Jochem; Przemysław Nowak; Ryszard Szkilnik; Eva Korossy-Mruk; Dariusz Boroń; Richard M Kostrzewa; Halina Brus; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

Review 5.  Histamine in the Crosstalk Between Innate Immune Cells and Neurons: Relevance for Brain Homeostasis and Disease.

Authors:  Liliana Bernardino
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 6.  Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.

Authors:  Mera Alhusaini; Nermin Eissa; Ali K Saad; Rami Beiram; Bassem Sadek
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

Review 7.  The histaminergic network in the brain: basic organization and role in disease.

Authors:  Pertti Panula; Saara Nuutinen
Journal:  Nat Rev Neurosci       Date:  2013-07       Impact factor: 34.870

8.  Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.

Authors:  Diego Baronio; Taylor Gonchoroski; Kamila Castro; Geancarlo Zanatta; Carmem Gottfried; Rudimar Riesgo
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

Review 9.  Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 10.  The Histaminergic System in Neuropsychiatric Disorders.

Authors:  Li Cheng; Jiaying Liu; Zhong Chen
Journal:  Biomolecules       Date:  2021-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.